Axogen Receives FDA Biologics License Approval for AVANCE Nerve Allograft, Marking Regulatory Milestone
核心洞察
The FDA has approved Axogen (搜索)'s Biologics License Application for AVANCE (搜索), an acellular nerve scaffold for treating peripheral nerve discontinuities (搜索) in patients aged one month and older.
The approval includes accelerated approval for sensory nerve gaps >25mm and mixed/motor nerve discontinuities based on static two-point discrimination outcomes.
This regulatory milestone transitions AVANCE (搜索) from a human tissue product classification to a biologic, strengthening Axogen (搜索)'s regulatory position.
Axogen (搜索), Inc. announced that the U.S. Food and Drug Administration has approved the Biologics License Application for AVANCE (搜索) (acellular nerve allograft-arwx (搜索)), marking a significant regulatory milestone for the peripheral nerve repair company. The approval covers treatment of adult and pediatric patients aged one month or older with sensory, mixed, and motor peripheral nerve discontinuities (搜索).
Accelerated Approval Pathway
The FDA granted approval for sensory nerve discontinuities greater than 25mm and for mixed and motor nerve discontinuities under the Accelerated Approval pathway. This decision was based on the effect on static two-point discrimination in sensory nerve gaps ≤25mm, which provided empirical evidence to reasonably predict clinical benefit given similarities in pathophysiology and anticipated therapeutic effects. Continued approval for these indications depends on verification and description of clinical benefit in confirmatory studies.
For sensory nerve discontinuities ≤25mm, AVANCE (搜索) received standard approval based on established clinical evidence.
Regulatory Classification Shift
"This approval represents a meaningful shift from our historical classification as a human tissue product and brings the product in line with FDA's classification of Avance (搜索) as a biologic," said Michael Dale, Axogen (搜索)'s Chief Executive Officer. "This milestone clarifies and strengthens our regulatory footing and confirms approval for use of Avance as an acceptable therapeutic option for treating peripheral nerve discontinuities (搜索) in all of Axogen's present nerve repair use cases."
The transition to biologic regulatory framework provides assurance that AVANCE (搜索) has been rigorously evaluated and determined to be safe, pure, and potent for its intended use, with benefits that outweigh known or potential risks.
Safety Profile and Adverse Events
The most common adverse reactions (≥2%) reported were procedural pain (4%) and hyperesthesia (3%). Healthcare providers must monitor for procedural complications including pain, hyperesthesia, infection, implant site swelling, adhesions, hypertrophic scar formation, impaired motor or sensory function, bleeding, and neuroma formation.
Because AVANCE (搜索) is manufactured from human donor tissue, it may carry a risk of transmitting infectious agents, including viruses, variant Creutzfeldt-Jakob disease (搜索) agent, and theoretically, the Creutzfeldt-Jakob disease (搜索) agent.
Commercial Timeline
Commercial availability of the licensed AVANCE (搜索) product is expected early in the second quarter of 2026. In the interim, AVANCE remains available under the current tissue framework, ensuring continued patient access during the transition period.
Dale emphasized the collaborative effort behind this achievement: "We want to thank FDA and the surgical community for the tremendous work and collaboration over more than a decade to make this therapy available to patients."
Company Portfolio
Axogen (搜索)'s product portfolio includes AVANCE (搜索) alongside Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. The company's products are available in the United States, Canada, Germany, the United Kingdom, Spain and several other countries.